How effective is infliximab for psoriasis?

Scientific studies have shown that the use of infliximab for psoriasis is highly effective in 70 to 75% of patients. This works by suppressing autoimmune reactions that cause excessive skin production causing psoriasis. However, infliximab carries the risk of serious side effects and should only be used in serious cases and when other treatment was ineffective or contraindicated.

Psoriasis is a inherited chronic autoimmune state that causes skin cells to replicate too quickly, leading to the accumulation of excess skin in plasses known as plaques. These plaques often occur on the outside of the joints, such as knees or elbows. The severity of psoriasis is generally measured on the severity of the psoriasis area (PASI). In patients with PASI 20 or higher scores, they have serious cases and are candidates for infliximab for psoriasis. The use of infliximab for psoriasis can clarify existing plaques and prevent new plaques, so far coléching continues.

Infliximab may be heavenFounded and it is not the first procedure recommended for the treatment of psoriasis. In general, suffering from psoriasis should first try over -the -counter and local medicines such as coal tar or salicylic acid products. If symptoms do not improve, the dermatologist can recommend phototherapy or other treatment such as ciclosporin or methotrexate. If this treatment does not work, or if the patient cannot take them, the potential benefits and risks of infliximab should be considered.

Infliximab works by suppressing the body's immune system; Therefore, it increases the susceptibility of the body to fungal, bacterial and viral infections, some of which may be serious or fatal. People who are wearers of diseases such as hepatitis B or tuberculosis are threatened by the development of active infections in the use of infliximab, so patients should be tested for these pathogens before the beginning of treatment. Infliximab may also increase the risks of liver disease, heart diseaseand some types of cancer, including leukemia and lymphoma. Patients who develop symptoms of any of these diseases in infliximab for psoriasis should immediately report them to doctors prescribing.

Infliximab is administered intravenously or via IV, so the treatment must be planned by a medical office or clinic. The typical infliximab treatment course for psoriasis consists of 3 to 5 milligrams per kilogram (2.2 pounds) of body weight, taking every two to three weeks. Each treatment takes about two hours. After 10 weeks, if a PASI is reduced by 75%, the doctor may prescribe either continued regular treatment or in need.